Precision BioSciences Inc DTIL.OQ DTIL.O is expected to show a fall in quarterly revenue when it reports results on November 4 for the period ending January 1 0001
The Durham North Carolina-based company is expected to report a 51.6% decrease in revenue to $6.356 million from $13.12 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Precision BioSciences Inc is for a loss of $1.92 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Precision BioSciences Inc is 30.00, above its last closing price of $8.56.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -1.68 | -1.50 | 4.67 | Beat | 410.3 |
Mar. 31 2024 | -2.01 | -1.91 | -0.35 | Beat | 81.7 |
Jan. 1 0001 | -3.99 | -2.05 | -4.06 | Missed | -98.3 |
Sep. 30 2023 | -5.03 | -4.87 | -2.10 | Beat | 56.9 |
Jun. 30 2023 | -7.52 | -7.32 | -3.00 | Beat | 59 |
Mar. 31 2023 | -6.80 | -6.78 | -6.90 | Missed | -1.8 |
Dec. 31 2022 | -6.48 | -6.22 | -6.60 | Missed | -25.3 |
Sep. 30 2022 | -7.63 | -7.95 | -6.60 | Beat | 17 |
This summary was machine generated November 1 at 13:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。